Tag:

Parkinson's

Latest Headlines

Latest Headlines

One big reason why CNS drug development has foundered

When you want to develop a drug for, say, cancer, objective measures such as survival rate can tell regulators just how effective it is compared to a standard drug or placebo. But in diseases involving the brain, scientists often have to settle for crude measures for assessing how patients perform or feel after treatment. And the wild card here is a placebo effect that can be very difficult to factor into studies and has been fingered for the death of multiple development programs.

Scripps investigators refine new drugs for Parkinson's disease

The Florida branch of The Scripps Research Institute is touting some new advances related to Parkinson's disease. Researchers say they have been working on new therapies that can precisely hit pathways critical for the death of brain cells, a hallmark of the disease. And they're now fine tuning their work by focusing on the oral bioavailability of their new drug candidates.

FDA approves AbbVie's Parkinson's drug, featuring delivery straight into the GI tract

The FDA just approved AbbVie's novel formulation of the standard Parkinson's drugs carbidopa and levodopa, Duopa, which is delivered straight into the patient's small intestine over 16 consecutive hours using an infusion pump and procedurally placed tube.

Patients respond positively to Cynapsus film strip of apomorphine to combat Parkinson's

Cynapsus reported that 14 of the 16 Parkinson's disease patients responded positively in the Phase II trial of its reformulated thin-film strip version of the drug apomorphine, dubbed APL-130277, for the treatment of "off" episodes.

Encapsulated Alzheimer's, Parkinson's-treating growth factors implanted directly in the brain

Scientists in Spain have now developed small particles with the ability to encapsulate growth factors when implanted in the brain, which could ultimately reverse the effects of these diseases by spurring the growth of new, healthy neurons.

Can't stop gambling or shopping? Parkinson's meds may be to blame, JAMA study finds

When Parkinson's disease patients start taking new meds, doctors go on the lookout for the usual side effects: dizziness, nausea, and the like. But according to a new study, they need to think weird, too. The risk of compulsive behavior--gambling, shopping, sex--is much higher than previously thought.

UPDATED: Acorda snags Phase III Parkinson's drug in $525M cash buyout

Acorda Therapeutics is gambling $525 million on a Phase III-ready Parkinson's treatment, striking an all-cash deal to buy Civitas Therapeutics.

Civitas, NeuroDerm, EyeGate to pursue IPO dreams, combined $165M on the line

Israel's NeuroDerm filed for a stock offering on the basis of its subcutaneous formulation for treating Parkinson's; Civitas, the developer of an inhaled formulation for the disease, is expected to debut on the Nasdaq Sept. 24; and EyeGate Pharmaceuticals, which employs low-voltage electrical current to deliver eye medication, also just filed for an IPO.

Acadia surges after nabbing 'breakthrough' title for late-stage Parkinson's drug

The FDA has just added a fresh boost to Acadia Pharmaceuticals, naming its late-stage Parkinson's drug pimavanserin a "breakthrough" therapy deserving rapid regulatory response as it nears the finish line with a closely watched marketing application.

Parkinson's play Civitas Therapeutics files for an $86M IPO

The S-1 prominently features Civitas' successful Phase IIb study for an inhaled formulation of levodopa, a "rescue" treatment for Parkinson's patients.